vida: extract claims from 2026-05-05-pmc12835689-semaglutide-atypical-anorexia-adolescent-case

- Source: inbox/queue/2026-05-05-pmc12835689-semaglutide-atypical-anorexia-adolescent-case.md
- Domain: health
- Claims: 2, Entities: 0
- Enrichments: 4
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/glp1-adolescent-eating-disorder-risk-amplified-by-developmental-timing.md

@@ -10,9 +10,16 @@ agent: vida
 sourced_from: health/2025-xx-pmc-glp1-eating-disorders-double-edged-sword.md
 scope: causal
 sourcer: PMC / Journal of Clinical Medicine
-related: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway"]
+related: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway", "glp1-adolescent-eating-disorder-risk-amplified-by-developmental-timing"]
 ---
 
 # Adolescents face compounded GLP-1 eating disorder risk because ED prevalence peaks during adolescence while social media exposure is highest
 
 The review identifies adolescents as the highest-risk population for GLP-1-induced eating disorder harm through a developmental timing mechanism. Two factors converge: (1) eating disorder prevalence peaks during adolescence, creating a large vulnerable population, and (2) adolescent social media use is highest, maximizing exposure to cosmetic GLP-1 promotion. This creates a compounding risk structure where the population most vulnerable to eating disorder onset is also most exposed to the cultural messaging that drives cosmetic GLP-1 misuse. The review explicitly names adolescents as an at-risk population requiring special consideration, alongside patients obtaining GLP-1s for cosmetic purposes without medical supervision and individuals with prior ED history. This is distinct from general GLP-1 eating disorder risk because it identifies a specific demographic where two independent risk factors (developmental vulnerability + cultural exposure) multiply rather than add.
+
+
+## Supporting Evidence
+
+**Source:** PMC12835689, January 2026
+
+Case of adolescent with 18-month pre-prescription restrictive history who developed life-threatening atypical anorexia nervosa (bradycardia 38 bpm, pericardial effusion, suicidal ideation) within 6 months of semaglutide initiation. The rapid progression from prescription to cardiac complications demonstrates that adolescent developmental stage compounds GLP-1 risk when behavioral substrate is present.

domains/health/glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge.md

@@ -38,3 +38,10 @@ ANAD's epistemic honesty is striking: 'We simply do not know if these medication
 **Source:** NBC News 2024-08-15
 
 Collaborative of Eating Disorders Organizations calling for mandatory screening before prescribing, indicating current practice lacks standardized pre-treatment ED assessment. No drug label warnings about ED risk exist as of August 2024 despite accumulating case reports.
+
+
+## Supporting Evidence
+
+**Source:** PMC12835689, January 2026
+
+General practitioner prescribed semaglutide to adolescent with 18 months of documented restrictive behaviors (increasing exercise, decreasing food intake, distorted body image) without psychological screening. The prescriber's failure to detect behavioral substrate that was present in patient history demonstrates screening gap is operational, not knowledge-based.

domains/health/glp1-pre-treatment-eating-disorder-screening-recommended-not-required.md

@@ -45,3 +45,10 @@ ANAD (the authoritative US professional society for eating disorders) formalizes
 **Source:** Northwestern Medicine JCI 2025
 
 The AgRP silencing mechanism strengthens the case for mandatory (not just recommended) pre-treatment screening. If semaglutide pharmacologically removes the biological safeguard against starvation, prescribing without ED screening is analogous to removing a safety system without checking if backup protections exist. The mechanism suggests screening should specifically assess for restrictive eating patterns, not just diagnosed eating disorders.
+
+
+## Challenging Evidence
+
+**Source:** PMC12835689, January 2026
+
+Case resulted in near-fatal cardiac complications (bradycardia 38 bpm, pericardial effusion) within 6 months of prescription to adolescent with undetected 18-month restrictive history. The severity and rapidity of outcome suggests screening should be mandatory requirement, not optional recommendation, for adolescent GLP-1 prescribing.

domains/health/glp1-prescribing-requires-eating-disorder-screening-infrastructure-to-prevent-catastrophic-outcomes-in-subclinical-restrictive-patients.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: Behavioral substrate for eating disorders exists undetected in patients without formal ED diagnosis, and GLP-1 appetite suppression compounds pre-existing restriction patterns into life-threatening outcomes when prescribers lack screening protocols
+confidence: experimental
+source: PMC12835689 case report, published January 2026
+created: 2026-05-05
+title: GLP-1 prescribing requires eating disorder screening infrastructure to prevent catastrophic outcomes in subclinical restrictive patients
+agent: vida
+sourced_from: health/2026-05-05-pmc12835689-semaglutide-atypical-anorexia-adolescent-case.md
+scope: causal
+sourcer: PMC12835689
+supports: ["glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "medical-care-explains-only-10-20-percent-of-health-outcomes-because-behavioral-social-and-genetic-factors-dominate"]
+related: ["glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "glp1-adolescent-eating-disorder-risk-amplified-by-developmental-timing", "glp1-starvation-spiral-hypothesis-caloric-deficit-triggers-obsessive-restriction", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-eating-disorder-pharmacovigilance-signal-class-effect-obesity-population-specific", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required"]
+---
+
+# GLP-1 prescribing requires eating disorder screening infrastructure to prevent catastrophic outcomes in subclinical restrictive patients
+
+This case documents an adolescent prescribed semaglutide who had 18 months of pre-prescription restrictive behaviors (increasing exercise, decreasing food intake, distorted body image) but no documented ED diagnosis. The prescriber proceeded without psychological screening. Within 6 months, the patient lost 20kg and developed cardiac complications (bradycardia 38 bpm, pericardial effusion) requiring psychiatric hospitalization after suicidal ideation. The proposed mechanism is that semaglutide's appetite suppression combined with underlying eating disorder psychopathology created compounding restriction effects. The critical insight is not that GLP-1 causes de novo ED, but that it catastrophically worsens subclinical restrictive patterns that are invisible without screening. The 18-month behavioral history proves the substrate existed before prescription. This is a screening failure, not a pharmacological causation case. The cardiac severity (near-fatal bradycardia and effusion within 6 months) demonstrates that undetected subclinical restriction + GLP-1 can produce life-threatening outcomes on a compressed timeline. The case establishes that behavioral assessment before GLP-1 prescription is not optional for adolescents—it is necessary infrastructure to prevent catastrophic outcomes in a population where restrictive behaviors are common but undiagnosed.

domains/health/glp1-starvation-spiral-hypothesis-caloric-deficit-triggers-obsessive-restriction.md

@@ -17,3 +17,10 @@ related: ["glp1-eating-disorder-pharmacovigilance-signal-class-effect-obesity-po
 # GLP-1-mediated caloric deficit may trigger starvation-response restriction through neurobiological misinterpretation of pharmacological appetite suppression as famine
 
 Multiple clinicians quoted in NBC News describe a progression pattern: beneficial appetite suppression → pathological restriction → 'atypical anorexia nervosa' presentation. The proposed mechanism is that the brain 'may interpret dramatic sudden weight loss as starvation, triggering obsessive food thoughts' — a neurobiological feedback loop where pharmacological caloric reduction activates evolutionary starvation-response circuits that then reinforce restriction behavior. The Cynthia Landrau case exemplifies this: 28-year-old consuming 'only about one-third of calories recommended for a woman her age' with 'no mentioned prior ED history' (though absence of evidence is not evidence of absence). This differs from the population-selection hypothesis (GLP-1s prescribed to people with subclinical ED risk) by proposing a direct pharmacological → neurological → behavioral pathway. Critical limitation: 'no mentioned prior history' ≠ 'confirmed no prior history' — the NBC reporter did not probe for subclinical body image concerns or dietary restriction patterns. All evidence is case-report level with no systematic data on incidence rates or risk factors.
+
+
+## Supporting Evidence
+
+**Source:** PMC12835689, January 2026
+
+Patient continued weight loss after semaglutide discontinuation at month 6, and experienced panic attack upon gaining 1kg with subsequent suicidal ideation. This progression demonstrates that GLP-1-initiated caloric deficit triggered self-sustaining obsessive restriction that persisted independent of the medication.

domains/health/glp1-worsens-pre-existing-subclinical-eating-disorders-rather-than-causing-de-novo-pathology.md

@@ -0,0 +1,19 @@
+---
+type: claim
+domain: health
+description: The strongest case evidence for GLP-1-associated eating disorder harm documents 18 months of pre-prescription restrictive behaviors, suggesting GLP-1 amplifies existing behavioral substrate rather than creating new psychiatric pathology
+confidence: experimental
+source: PMC12835689 case report, January 2026
+created: 2026-05-05
+title: GLP-1 worsens pre-existing subclinical eating disorders rather than causing de novo pathology
+agent: vida
+sourced_from: health/2026-05-05-pmc12835689-semaglutide-atypical-anorexia-adolescent-case.md
+scope: causal
+sourcer: PMC12835689
+supports: ["glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive"]
+related: ["glp1-eating-disorder-causality-expert-divergence-reflects-evidence-gap", "glp1-eating-disorder-risk-subtype-specific-protective-bed-harmful-restrictive", "glp1-starvation-spiral-hypothesis-caloric-deficit-triggers-obsessive-restriction", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-eating-disorder-pharmacovigilance-signal-class-effect-obesity-population-specific", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway"]
+---
+
+# GLP-1 worsens pre-existing subclinical eating disorders rather than causing de novo pathology
+
+This case report, described by curators as 'the strongest individual case in the literature,' documents an adolescent who developed severe atypical anorexia nervosa during semaglutide treatment. However, detailed history reveals 18 months of pre-prescription concerning behaviors: increasing exercise, decreasing food intake, and distorted body image. The patient was prescribed semaglutide for being 'on the verge of being overweight with weight-related dysphoria'—language that itself suggests body image distortion. The rapid progression (20kg loss in 6 months, cardiac complications including bradycardia 38 bpm and pericardial effusion) demonstrates that GLP-1's appetite suppression mechanism interacted with pre-existing restrictive patterns to create a compounding effect. The authors propose that 'semaglutide can affect mental health in patients who are prone to mental disorders.' This case challenges the narrative that GLP-1 causes de novo eating disorders and instead suggests it catastrophically worsens subclinical restriction that exists below diagnostic thresholds. The 18-month behavioral history is the critical evidence: the substrate was present before the drug. This distinction matters for clinical policy—it suggests the intervention point is screening for behavioral antecedents, not avoiding GLP-1 entirely in vulnerable populations.

inbox/archive/health/2026-05-05-pmc12835689-semaglutide-atypical-anorexia-adolescent-case.md

@@ -7,10 +7,13 @@ date: 2026-01-01
 domain: health
 secondary_domains: []
 format: article
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-05
 priority: high
 tags: [glp-1, semaglutide, eating-disorders, anorexia, atypical-anorexia, case-report, adolescent, screening-failure]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content